Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesProthena Corp. PLC

Prothena Corp. PLC

PortfolioPortfolio WatchlistWatchlist
Company price
8.5135 GBX 0.09 ( 1.11%)
Last update at 2026-10-27T15:21:00Z
VOLUME
3
Market Cap
33754.29M
P/E
0.08

Momentum Score

…

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.14
Low
8.51
High
52 Week Price Range
4.34
Low
11.67
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
8.42
Dividend Yield
-
Revenue TTM
9.68M
Revenue Per Share
0.18
Gross Profit TTM
-125.17M
Debt / Equity
0.15
ROE
-63.62%
Net Debt
-
ROCE
-42.83%
Diluted EPS TTM
1.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - - -111.43M -77.30M -156.12M
Net income - - -111.14M -77.68M -155.65M
Selling general administrative - - 38.70M 35.74M 42.48M
Ebit -131.56M 71.97M -112.73M -85.76M -142.71M
Operating income - - -112.73M -85.70M -158.85M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Tax provision - - -0.28M 0.38M -0.47M
Interest income - - 1.37M 8.20M 2.69M
Income tax expense -8.66M 4.95M -0.28M 0.38M -0.47M
Total revenue - - 0.85M 0.81M 0.95M
Net income applicable to common shares -116.95M 66.97M -111.14M -77.68M -155.65M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - - 332.98M 419.27M 498.80M
Other current assets 1.71M 0.77M 1.35M - 3.73M
Total liab - - 148.97M 146.35M 175.80M
Total stockholder equity - - 184.01M 272.92M 323.00M
Other current liab 11.95M 8.06M 0.55M 0.33M 0.84M
Common stock 0.52M 0.47M 0.40M 0.40M 0.40M
Retained earnings -833.00M -716.05M -783.03M -671.88M -598.00M
Other liab 85.85M 103.49M 110.80M 110.80M 110.97M
Other assets 30.93M 10.42M 13.33M 13.74M 14.57M
Cash - - 295.38M 375.72M 427.66M
Total current liabilities 50.15M 33.45M 25.85M 17.71M 14.93M
Short long term debt total - - - - 49.90M
Property plant equipment 8.01M 14.13M 20.36M 27.15M 52.84M
Total current assets 719.10M 584.81M 299.28M 378.38M 431.39M
Net tangible assets 622.04M 466.04M 184.01M 272.92M 323.00M
Net receivables 0.06M 0.01M 0.01M 0.07M 0.00M
Accounts payable 9.27M 3.69M 4.12M 1.24M 1.47M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Change to liabilities - - -1.99M -0.14M 7.73M
Total cashflows from investing activities - - -0.46M -0.57M -0.20M
Total cash from financing activities - - 241.46M 190.33M 0.21M
Change to operating activities - - -16.81M -10.26M -4.25M
Net income -122.31M -147.03M -116.95M 66.97M -111.14M
Change in cash - - 132.17M 282.36M -80.34M
Total cash from operating activities - - -108.82M 92.61M -80.36M
Depreciation - - 6.74M 6.80M 6.98M
Change to account receivables - - - 0.01M 0.05M
Sale purchase of stock - - - - 0.21M
Change to netincome - - 20.19M 29.23M 20.33M
Capital expenditures 0.00M 0.00M 0.46M 0.57M 0.20M
Change in working capital - - - - 3.48M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0Y3M
Prothena Corp. PLC		 0.09
1.11%		 8.51 0.08 - 34.86 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Prothena Corp. PLC

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60

353 1 236 2500

https://www.prothena.com

67

Name Title Year Born
Dr. Gene G. Kinney Ph.D. Pres, CEO & Director 1969
Mr. Tran B. Nguyen M.B.A. CFO & Chief Strategy Officer 1974
Mr. Brandon S. Smith Chief Operating Officer 1975
Ms. Carol D. Karp Chief Regulatory Officer 1953
Dr. Hideki Garren M.D., Ph.D. Chief Medical Officer 1965
Ms. Karin L. Walker CPA, CPA Chief Accounting Officer & Controller 1963
Dr. Wagner M. Zago Chief Scientific Officer 1973
Ms. Jennifer Zibuda Director of Investor Relations & Communication NA
Mr. Michael J. Malecek Chief Legal Officer 1966
Ms. Yvonne M. Tchrakian Company Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…